Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325820 | 1.00 | BRD4 (0.31) | BRD4SIGMAR1 | |
| SCHEMBL24179738 | 0.79 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL14104187 | 0.78 | SIGMAR1 (0.38) | SIGMAR1 | |
| SCHEMBL27387361 | 0.78 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL1191024 | 0.78 | SIGMAR1 (0.33) | SIGMAR1 | |
| SCHEMBL17366100 | 0.76 | — | — | |
| SCHEMBL25154343 | 0.74 | TSHR (0.36) | SIGMAR1 | |
| SCHEMBL25154327 | 0.74 | TSHR (0.36) | SIGMAR1 | |
| SCHEMBL25154637 | 0.74 | TSHR (0.36) | SIGMAR1 | |
| SCHEMBL1190409 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220089613-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2022-03-24 | — | — | US | disclosed |
| US-20220089613-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2022-03-24 | — | — | US | disclosed |
| US-11220518-B2 | Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-11220518-B2 | Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors | PFIZER INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-10316045-B2 | Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316045-B2 | Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors | PFIZER INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2017-08-03 | — | — | US | disclosed |
| US-8877761-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877761-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20120202809-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202809-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-20120202809-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PFIZER INC. | 2012-08-09 | — | — | US | disclosed |
| US-8183255-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183255-B2 | N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole derivatives as PKC kinase inhibitors | PFIZER, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | PFIZER INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217991-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | INSR, IAPP, GPR119 | BRD4 277/4885SIGMAR1 3033/4885 |
| US-10316045-B2 | Substituted pyrrolo[3,4-c]pyrazoles as pkc kinase inhibitors | PRKCB, PRKCA, PRKCE | BRD4 1320/4885SIGMAR1 3165/4885 |
| US-11780853-B2 | Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors | PRKCB, PRKCA, PRKCQ | BRD4 1061/4885SIGMAR1 3047/4885 |
| US-11220518-B2 | Substituted n-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazoles as protein kinase C inhibitors | JAK3, PRKCB, PRKCA | BRD4 470/4885SIGMAR1 3440/4885 |
| US-20100130501-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H, 6H) CARBALDEHYDE DERIVATIVES | DPP3, IAPP, GPR119 | BRD4 218/4885SIGMAR1 3234/4885 |
| US-20220089613-A1 | NOVEL 3-AMINO-PYRROLO[3,4-C]PYRAZOLE-5(1H, 4H,6H) CARBALDEHYDE DERIVATIVES | INSR, IAPP, GPR119 | BRD4 277/4885SIGMAR1 3033/4885 |
| US-20120202809-A1 | NOVEL N-PYRIMIDIN-4-YL-3-AMINO-PYRROLO[3,4-C]PYRAZOLE DERIVATIVES AS PKC KINASE INHIBITORS | PRKCB, PRKCA, PRKCE | BRD4 1157/4885SIGMAR1 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.